Priovant Therapeutics News and Activities

Priovant Therapeutics is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1476);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 20 subsidiaries including Aetion, Aramis Biosciences and Asahi Chemical.

They are in:

• Biotechnology52%
• Chemicals24%
• Other24%

View the org chart displaying its 50 main executives

Most searched biographies at Priovant Therapeutics

• Benjamin Zimmer, Chief Executive Officer
• Irena Melnikova, Director
• Frank Torti, Executive Chairman of the Board

Popular executive movements at Priovant Therapeutics

• Tyler Massaro, who was Director, Biostatistics, is promoted to Senior Director, Biostatistics and Programming  (posted on April 16 2026).
• Sasha Goriounova who was Senior Manager, Clinical Development, becomes Associate Director, Clinical Development  (posted on April 16 2026).

Create your alert
to follow the executive moves at Priovant Therapeutics.

Sumitomo Chemical has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Priovant Therapeutics

• Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
• New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
• Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
• Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
• Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
• Priovant Therapeutics
• Priovant Therapeutics Announces Receipt of Fast Track Designation from FDA for Brepocitinib in Non-Anterior Non-Infectious Uveitis (NIU) & Start of Enrollment of Brepocitinib Phase 3 NIU Program
• Priovant Therapeutics Announces Completion of Enrollment in Global Phase 3 Study Evaluating Brepocitinib in Dermatomyositis (VALOR)
• Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date
• Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
• View more press releases Close

Social media about Priovant Therapeutics

• Priovant Therapeutics on Wikipedia, Google News & Yahoo Finance
• Priovant Therapeutics on LinkedIn, X (Twitter) & YouTube